These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448 [TBL] [Abstract][Full Text] [Related]
5. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Spreemann T; Bertram H; Happel CM; Kozlik-Feldmann R; Hansmann G Pulm Circ; 2018; 8(1):2045893217743123. PubMed ID: 29099661 [TBL] [Abstract][Full Text] [Related]
6. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Schuuring MJ; Vis JC; Duffels MG; Bouma BJ; Mulder BJ Ther Clin Risk Manag; 2010 Sep; 6():359-66. PubMed ID: 20856682 [TBL] [Abstract][Full Text] [Related]
7. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. Yao A J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290 [TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases. Smukowska-Gorynia A; Gościniak W; Woźniak P; Iwańczyk S; Jaxa-Kwiatkowska K; Sławek-Szmyt S; Janus M; Paluszkiewicz J; Mularek-Kubzdela T Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765060 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Lan NSH; Massam BD; Kulkarni SS; Lang CC Diseases; 2018 May; 6(2):. PubMed ID: 29772649 [TBL] [Abstract][Full Text] [Related]
10. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530 [TBL] [Abstract][Full Text] [Related]
11. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension. Wu S; Hoang HB; Yang JZ; Papamatheakis DG; Poch DS; Alotaibi M; Lombardi S; Rodriguez C; Kim NH; Fernandes TM Chest; 2022 Dec; 162(6):1360-1372. PubMed ID: 35841932 [TBL] [Abstract][Full Text] [Related]
12. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Badlam JB; Bull TM Ther Adv Chronic Dis; 2017 Feb; 8(2-3):47-64. PubMed ID: 28348727 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Kaemmerer H; Gorenflo M; Huscher D; Pittrow D; Apitz C; Baumgartner H; Berger F; Bruch L; Brunnemer E; Budts W; Claussen M; Coghlan G; Dähnert I; D'Alto M; Delcroix M; Distler O; Dittrich S; Dumitrescu D; Ewert R; Faehling M; Germund I; Ghofrani HA; Grohé C; Grossekreymborg K; Halank M; Hansmann G; Harzheim D; Nemes A; Havasi K; Held M; Hoeper MM; Hofbeck M; Hohenfrost-Schmidt W; Jurevičienė E; Gumbienè L; Kabitz HJ; Klose H; Köhler T; Konstantinides S; Köestenberger M; Kozlik-Feldmann R; Kramer HH; Kropf-Sanchen C; Lammers A; Lange T; Meyn P; Miera O; Milger-Kneidinger K; Neidenbach R; Neurohr C; Opitz C; Perings C; Remppis BA; Riemekasten G; Scelsi L; Scholtz W; Simkova I; Skowasch D; Skride A; Stähler G; Stiller B; Tsangaris I; Vizza CD; Vonk Noordegraaf A; Wilkens H; Wirtz H; Diller GP; Grünig E; Rosenkranz S J Clin Med; 2020 May; 9(5):. PubMed ID: 32414075 [TBL] [Abstract][Full Text] [Related]
14. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Sulica R; Fenton R; Cefali F Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969 [TBL] [Abstract][Full Text] [Related]
15. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat]. Gratsianskaya SE; Valieva ZS; Martynyuk TV Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435 [TBL] [Abstract][Full Text] [Related]
16. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774 [TBL] [Abstract][Full Text] [Related]